The HIF-1α/PKM2 Feedback Loop in Relation to EGFR Mutational Status in Lung Adenocarcinoma

Figures & data

Figure 1. EGFR mutational status of lung adenocarcinoma (LUAD). Abbreviation: EGFR-mt, EGFR mutation adenocarcinoma; EGFR-wd, EGFR wild type adenocarcinoma.

Table 1. The clinicopathological features of 89 LUAD patients.

Clinical characteristics	Overall n	EGFR-mt n (%)	EGFR-wd n (%)	P value
All	89	44	45
Age
<60 years	33	14	19	0.310
≥60 years	56	30	26
Gender
Male	40	10	30	<0.001
Female	49	34	15
Smoking
Never	55	36	19	<0.001
ever	34	8	26
Stage
I	49	24	25	0.964
II	17	8	9
III	15	10	5
IV	8	2	6

Abbreviation: EGFR, epidermal growth factor receptor; LUAD, lung adenocarcinoma; EGFR-mt, EGFR mutation lung adenocarcinoma; EGFR-wd, EGFR wild type lung adenocarcinoma.

Figure 2. Different expressions of HIF-1α and PKM2 in normal lung tissue (NLT) and lung adenocarcinoma (LUAD).

Table 2. Expressions of HIF-1α and PKM2 in normal lung tissue and lung adenocarcinoma.

	HIF-1α		PKM2
	+	−	+	−
NLT	41	48	28	61
LUAD	56	33	50	39
P value	0.024		0.001

Abbreviation: NLT, normal lung tissue; HIF-1α, hypoxia-inducible factor-1α; PKM2, Pyruvate kinase M2.

Table 3. Relationship between the expression of HIF-1α and PKM2 in lung adenocarcinoma.

		HIF-1α
		+	−
PKM2	+	38	12
	−	18	21
p = 0.003, r = 0.307

Table 4. Relationships of HIF-1α/PKM2 feedback loop proteins with clinical pathological characteristics in adenocarcinomas of lung.

Clinical characteristics		HIF-1α			PKM2
	overall	+	−	P value	+	−	P value
All	89	56	33		50	39
Age
<60 years	33	20	13	0.728	17	16	0.496
≥60 years	56	36	20		33	23
Gender
Male	40	22	18	0.162	25	15	0.278
Female	49	34	15		25	24
Smoking
Never	55	37	18	0.280	32	23	0.628
Ever	34	19	15		18	16
Stage
I	49	26	23	0.023	22	27	0.023
II	17	11	6		12	5
III	15	13	2		10	5
IV	8	6	2		6	2

Figure 3. Different expressions of HIF-1α and PKM2 in EGFR wild type (EGFR-wd) and EGFR mutation (EGFR-mt) lung adenocarcinomas.

Table 5. HIF-1α and PKM2 protein expressions in EGFR wild-type versus EGFR-mutated lung adenocarcinoma.

	HIF-1α		PKM2
	+	−	+	−
EGFR-mt	35	9	30	14
EGFR-wd	21	24	20	25
P value	0.001		0.033

Abbreviation: EGFR-mt, EGFR mutation lung adenocarcinoma; EGFR-wd, EGFR wild type lung adenocarcinoma.

Table 6. Relationship between the expression of HIF-1α and PKM2 protein in EGFR wild-type versus EGFR-mutated lung adenocarcinoma.

		HIF-1α
		EGFR-mt		EGFR-wd
		+	−	+	−
PKM2	+	27	3	11	9
	−	8	6	10	15
		p = 0.011, r = 0.379		p = 0.327, r = 0.149

Abbreviation: EGFR-mt, EGFR mutation lung adenocarcinoma; EGFR-wd, EGFR wild type lung adenocarcinoma.

Table 7. Relationships of HIF-1α/PKM2 feedback loop proteins with clinical pathological characteristics in EGFR wild-type versus EGFR-mutated lung adenocarcinoma.

		EGFR-mt						EGFR-wd
		HIF-1α			PKM2			HIF-1α			PKM2
Clinical characteristics	Overall	+	−	P	+	−	P	+	−	P	+	−	P
All	89	35	9		30	14		21	24		20	25
Age
<60 years	33	11	3		9	5		9	10		8	11
≥60 years	56	24	6	1.000	21	9	0.975	12	14	0.936	12	14	0.787
Gender
Male	40	7	3		9	1		15	15		16	14
Female	49	28	6	0.685	21	13	0.194	6	9	0.526	4	11	0.090
Smoking
Never	55	29	7		24	12		8	11		8	11
ever	34	6	2	1.000	6	2	0.970	13	13	0.600	12	14	0.787
Stage
I	49	16	8		14	11		10	15		8	17
II	17	7	1		5	3		4	5		7	2
III	15	10	0		9	1		3	2		1	4
IV	8	2	0	0.030	2	0	0.062	4	2	0.227	4	2	0.123

Abbreviation: EGFR-mt, EGFR mutation adenocarcinoma; EGFR-wd, EGFR wild type adenocarcinoma.